← Trials/Trial dossier/NCT01931982

EGOFIP

CompletedPhase 4

Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.

Effect of GLP-1 on Microvascular Myocardial Function in Patients With Type 2

Lead sponsor

Bispebjerg Hospital

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI ≥25•HbA1c 6-10%

Primary endpoint

•Coronary flow reserve (CFR)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01931982

Org study IDeudraCT: 2012-005013-38

Secondary ID2012-005013-38

Timeline

Milestones

Study first posted2013-08-30estimated

Last update posted2014-06-25estimated

Study start2013-05 (month precision)

Primary completion2014-04actual (month precision)

Study completion2014-04actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age25 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy of metformin and sulfonylurea.

•Age: 25-75 years

•BMI>25 kg/m2

•HbA1c 6,0-10 %

Exclusion criteria

•Current treatment with insulin or Dipeptidyl peptidase IV inhibitor.

•Haemoglobin < 6.5 mmol/l

•Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CT-angiography or regional dysfunction documented during dipyridamol stress-echocardiography. If stress test at baseline shows significant stenosis the patient will be excluded from the study.

•Allergy towards victoza ® (liraglutide ), Dipyridamol, Nitroglycerin or rescue medicine: Theophyllin

•Pregnancy

•Severe asthma

•Active cancer

•Severe co-morbidity with limited life-expectancy

•Estimated glomerular filtration rate (eGFR) <60 (measured at baseline)

•Severe hepatic co-morbidity

•Chronic alcohol abuse

•Heart failure with a left ventricular ejection fraction </= 45%

•Atrial fibrillation

•Chronic or previous acute pancreatitis

•Inflammatory bowel disease.

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

Cardiometabolic biomarkers

Other (unclassified)

Weight & body composition

2 endpoints

Other/protocol endpoint

Change in weight

Time frame:Weight is measured at baseline and after 10 weeks of intervention

Body weight, absolute change (kg)

change from baseline, improvement

Other/protocol endpoint

Change in waist circumference

Time frame:Waist circumference is measured at baseline and after 10 weeks of intervention

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

4 endpoints

Other/protocol endpoint

Changes in HbA1c

Time frame:Measurements at baseline and after 10 weeks of intervention

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other/protocol endpoint

Change in fasting C-peptide

Time frame:C-peptide is measured at baseline and after 10 weeks of intervention

change from baseline, improvement

Other/protocol endpoint/low confidence

Change in fasting insulin

Time frame:Fasting insulin is measured at baseline and after 10 weeks of intervention

change from baseline, improvement

Other/protocol endpoint

Change in fasting glucose

Time frame:Fasting glucose is measured at baseline and after 10 weeks of intervention

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Cardiometabolic biomarkers

1 endpoint

Secondary/protocol endpoint

Change in Endothelial function:

Time frame:Endothelial function is measured at baseline and after 10 weeks of intervention

change from baseline, improvement

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Change in coronary flow reserve (CFR)

Time frame:CFR is measured at baseline and after 10 weeks of intervention

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
Cardiovascular diabetology2015 Apr 22PMID25896352doi:10.1186/s12933-015-0206-3via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.